– CANADA, Toronto – Highland Therapeutics Inc. today announced the appointment of Stephanie Read to its Board of Directors, effective November 13, 2020.
Ms. Read brings to the Company a wealth of experience and expertise gained from over twenty years of tenure in the pharmaceuticals industry, including in the ADHD market.
“It is my pleasure to welcome Ms. Read, an accomplished executive, to the Highland Board of Directors,” said Chairman and CEO, David Lickrish. “Ms. Read’s leadership skills encompass a wide range of functional areas, including corporate strategy, business development, and product development through successful commercial launch, and she has proven expertise in strategies to unlock the potential of novel assets with unique delivery systems. Also, her deal-making experience and global network will serve us well as we look to expand the availability of JORNAY PM® internationally, as well as to pursue in-licensing opportunities to leverage our specialty sales force, which is focused on supporting pediatricians and psychiatrists. Ms. Read has already made substantial contributions and I very much look forward to working with her, as Highland continues its evolution as a fully integrated pharmaceutical company.”
About Stephanie Read
Ms. Read currently serves as VP, Strategy, and Development for CSL Limited, a global pharmaceutical company that generated operating revenues of over US$9 billion in the 2019/2020 fiscal year. Before joining CSL in 2015, she was Executive Director, Corporate Strategy and Ventures at AstraZeneca/MedImmune. Earlier in her career, she served as Associate Director, Global Medical Affairs for Shire Pharmaceuticals.
Ms. Read said, “I am very pleased to join the Highland Board of Directors. In my short tenure, I have been impressed with the Company’s patient-focused approach to medicines development and rapidly evolving strategies to expand patient access as a key component of the recent JORNAY PM launch. The DELEXIS drug-delivery system has exciting potential across multiple disease states that could benefit from once-daily, sustained-release delivery to the colon in a non-pH-dependent manner. I believe Highland is well-positioned to achieve its objectives and I am eager to contribute to its success.”
Ms. Read holds an M.Sc. in Biotechnology from Johns Hopkins University and a B.Sc. from Virginia Tech.
About Highland Therapeutics Inc.
Through its wholly-owned subsidiary, Ironshore Pharmaceuticals & Development, Inc., Highland developed JORNAY PM, the first and only stimulant medication that is dosed in the evening, demonstrating improvement in the severity of ADHD symptoms in the early morning and throughout the day. JORNAY is distributed in the U.S. by Ironshore Pharmaceuticals Inc.
For more information: https://www.highlandtherapeutics.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.